Innate Pharma (IPHYF) 9.8600 $IPHYF
INNATE PHARMA APPOINTS PIERRE DODION AS CHIEF MEDICAL OFFICER AND MEMBER OF THE EXECUTIVE COMMITTEE
GlobeNewswire - Tue Sep 16, 11:40AM CDT
-- Marcel Rozencweig becomes President of Innate Pharma Inc., based in the US
Innate Pharma SA concludes target enrollment of 150 Acute Myeloid Leukemia patients in EffiKIR trial
M2 - Fri Jul 25, 4:59AM CDT
Biopharmaceutical company Innate Pharma SA (Euronext Paris: FR0010331421) revealed on Thursday that it has completed target enrollment in the EffiKIR trial with 150 Acute Myeloid Leukemia (AML) patients randomised.
INNATE PHARMA : Completion of target enrollment in the phase II EffiKIR trial
GlobeNewswire - Thu Jul 24, 12:36AM CDT
-- Data on primary efficacy endpoint Leukemia-Free Survival expected end of 2015
Innate Pharma SA begins Phase I trial with lirilumab and nivolumab in selected solid tumors under cohort expansion
M2 - Mon Mar 31, 4:36AM CDT
Biopharmaceutical company Innate Pharma SA (Euronext Paris: FR0010331421) reported on Monday that it has started the cohort expansion portion of the Phase I clinical trial testing the combination of the two investigational checkpoint inhibitors lirilumab and nivolumab in selected solid tumors.
INNATE PHARMA : Start of cohort expansion of Phase I trial with lirilumab and nivolumab in selected solid tumors
GlobeNewswire - Mon Mar 31, 12:50AM CDT
Start of cohort expansion of Phase I clinical trial testing the combination of lirilumab and nivolumab in selected solid tumors
INNATE PHARMA : announces first DSMB review of ongoing EffiKIR Phase II trial with lirilumab
GlobeNewswire - Tue Sep 17, 1:34AM CDT
Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, today announces that the Data and Safety Monitoring Board ("DSMB"
completed its first assessment of the EffiKIR study and unanimously recommended continuation of the trial without modification.
Cutaneous T-Cell Lymphoma - Latest Pipeline Review Report
M2 - Fri Jul 12, 6:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q8vtbk/cutaneous_tcell) has announced the addition of the "Cutaneous T-Cell Lymphoma - Pipeline Review, H2 2012" report to their offering. 'Cutaneous T-Cell Lymphoma - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cutaneous T-Cell Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cutaneous T-Cell Lymphoma. Scope - A snapshot of the global therapeutic scenario for Cutaneous T-Cell Lymphoma. - A review of the Cutaneous T-Cell Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipel
Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2013 Report
M2 - Wed Jun 19, 6:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jbrmql/cutaneous_tcell) has announced the addition of the "Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2013" report to their offering. "Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2013", provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cutaneous T-Cell Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Cutaneous T-Cell Lymphoma. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Cutaneous T-Cell Lymphoma pipeline depth and focus of Indication th
Sezary Syndrome - Pipeline Review, H1 2013 Contains Latest News and Deals Relating to the Products
M2 - Fri Jun 07, 9:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2npr37/sezary_syndrome) has announced the addition of the "Sezary Syndrome - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Sezary Syndrome - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Sezary Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Sezary Syndrome. Sezary Syndrome - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Sezary Syndrom
INNATE PHARMA APPOINTS PIERRE DODION AS CHIEF MEDICAL OFFICER AND MEMBER OF THE EXECUTIVE COMMITTEE
GlobeNewswire - Tue Sep 16, 11:40AM CDT
-- Marcel Rozencweig becomes President of Innate Pharma Inc., based in the US
Innate Pharma SA concludes target enrollment of 150 Acute Myeloid Leukemia patients in EffiKIR trial
M2 - Fri Jul 25, 4:59AM CDT
Biopharmaceutical company Innate Pharma SA (Euronext Paris: FR0010331421) revealed on Thursday that it has completed target enrollment in the EffiKIR trial with 150 Acute Myeloid Leukemia (AML) patients randomised.
INNATE PHARMA : Completion of target enrollment in the phase II EffiKIR trial
GlobeNewswire - Thu Jul 24, 12:36AM CDT
-- Data on primary efficacy endpoint Leukemia-Free Survival expected end of 2015
Innate Pharma SA begins Phase I trial with lirilumab and nivolumab in selected solid tumors under cohort expansion
M2 - Mon Mar 31, 4:36AM CDT
Biopharmaceutical company Innate Pharma SA (Euronext Paris: FR0010331421) reported on Monday that it has started the cohort expansion portion of the Phase I clinical trial testing the combination of the two investigational checkpoint inhibitors lirilumab and nivolumab in selected solid tumors.
INNATE PHARMA : Start of cohort expansion of Phase I trial with lirilumab and nivolumab in selected solid tumors
GlobeNewswire - Mon Mar 31, 12:50AM CDT
Start of cohort expansion of Phase I clinical trial testing the combination of lirilumab and nivolumab in selected solid tumors
INNATE PHARMA : announces first DSMB review of ongoing EffiKIR Phase II trial with lirilumab
GlobeNewswire - Tue Sep 17, 1:34AM CDT
Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, today announces that the Data and Safety Monitoring Board ("DSMB"
completed its first assessment of the EffiKIR study and unanimously recommended continuation of the trial without modification. Cutaneous T-Cell Lymphoma - Latest Pipeline Review Report
M2 - Fri Jul 12, 6:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q8vtbk/cutaneous_tcell) has announced the addition of the "Cutaneous T-Cell Lymphoma - Pipeline Review, H2 2012" report to their offering. 'Cutaneous T-Cell Lymphoma - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cutaneous T-Cell Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cutaneous T-Cell Lymphoma. Scope - A snapshot of the global therapeutic scenario for Cutaneous T-Cell Lymphoma. - A review of the Cutaneous T-Cell Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipel
Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2013 Report
M2 - Wed Jun 19, 6:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jbrmql/cutaneous_tcell) has announced the addition of the "Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2013" report to their offering. "Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2013", provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cutaneous T-Cell Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Cutaneous T-Cell Lymphoma. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Cutaneous T-Cell Lymphoma pipeline depth and focus of Indication th
Sezary Syndrome - Pipeline Review, H1 2013 Contains Latest News and Deals Relating to the Products
M2 - Fri Jun 07, 9:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2npr37/sezary_syndrome) has announced the addition of the "Sezary Syndrome - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Sezary Syndrome - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Sezary Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Sezary Syndrome. Sezary Syndrome - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Sezary Syndrom
